A prospective study by Suzuki et al. demonstrated that COPD patients treated with nivolumab experienced significant increases in FVC and FEV1, suggesting a potential beneficial effect of PD-1 inhibition on lung function [44]. This evidence concerns the gene PDCD1 and chronic obstructive pulmonary disease.